Healthcare Affordability
Expert articles and analysis related to healthcare affordability.
AI Summary — Last 7 Days
CMS is pushing affordability through more compulsory payment reform, finalizing a 2027 inpatient hospital update alongside the first nationwide mandatory joint-replacement bundle launching in 2028—an escalation that hospitals view as underfunded and overly prescriptive, but that signals renewed federal appetite for specialty-led cost control under the Trump administration. At the same time, Medicaid and dual-eligible budget pressure is moving nursing-home care toward value-based arrangements, while Medicare Advantage plans such as Clover are leaning on Stars performance and membership growth to sustain the VBC business case. The core tension for ACOs, hospitals, and payers is sharpening: federal and state purchasers want faster savings from mandatory models, AI-enabled utilization management, and risk contracting, but providers are warning that thin rate updates and administrative burden could undermine participation and care transformation (CMS inpatient rule and mandatory joint-replacement model; dual-eligible nursing-home shift toward VBC
Related Articles
How Much and Why ACA Marketplace Premiums Are Going Up in 2027
ACA Marketplaces insurers are proposing a median premium increase of 15% in 2027, according to KFF's updated analysis of 276 insurers with publicly available filings across all 50 states and the Distr...
HRSA sets 2027 launch for the 340B rebate model, announces requirements
The Health Resources and Services Administration (HRSA) followed through with plans to pilot a rebate model for the 340B Drug Pricing Program beginning Jan. 1, 2027. As described in a notice published...
Nathan Kaufman: A tragedy of epic proportions looms for healthcare
Garrett Hardin popularized the idea of a tragedy of the commons in a 1968 Science essay carrying that title.a It describes a situation in which individuals with unlimited access to a public resource a...
Trump administration tries again to institute rebates in 340B
The Health Resources and Services Administration is again pushing to include rebates in the drug discount program after a failed attempt earlier this year. Hospitals railed against the announcement, s...
The government is forcing PBMs to be more transparent, but will reforms make a difference?
The Consolidated Appropriations Act, passed in February, included several significant reforms for PBMs.
How hospitals can prepare for heightened 340B oversight
Momentous change may be looming for the 340B Drug Pricing Program, currently managed by the Health Resources & Services Administration (HRSA). An ongoing debate regarding the program’s effectiveness r...
STAT+: Trump administration revises rebate pilot for 340B drug discount program, angering hospitals
The Trump administration is revising its rebate pilot for the 340B drug discount program, angering hospitals.
The Collision Of 340B Pricing And Medicare Drug Price Negotiation
The Collision Of 340B Pricing And Medicare Drug Price Negotiation Health Affairs
STAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricing
Lilly was accused of charging “grossly” excessive prices for different insulin products that forced some patients to ration or forgo the drug.
Pharma groups back changes to 340B rebate pilot
HHS' Health Resources and Services Administration unveiled details of a revised 340B rebate pilot, which will let some drug manufacturers deny rebates for a small subset of drugs. The 340B program g...